Publications
Evaluating the real-world impact of atezolizumab and bevacizumab combination in unresectable hepatocellular carcinoma: A south Indian experience.
Sireesh Kumar Ch, Gangadharan Kv, Sreelesh Kombath Payini, Arun Chandrasekhar, Sarah Valson, Sreedhar Cherulil, Anuja MS, Amrutha Nidhin, Zerin Haris Background: The combination of atezolizumab and bevacizumab emerged as first-line systemic therapy in unresectable hepatocellular Carcinoma (uHCC), demonstrating promising efficacy in clinical trials. However, real-world data on its safety and efficacy remains crucial to understanding its broader clinical application. Methods: This retrospective cohort study included uHCC patients treated with atezolizumab and bevacizumab from January 2021 to January 2025 in a tertiary care centre. Data on demographics, clinical characteristics, and outcomes [Progression free survival (PFS), Overall survival (OS), adverse events] were collected. Safety was evaluated through treatment-related adverse events, including immune-related and vascular complications. Results: A total of 21 patients with uHCC were included in the analysis (Table 1). The median age of the cohort was 69 years (59.5–72.5 years), with a …
